[P3] B

[P3-017-B] Onset and duration of protection of a new ready-to-use PCV-2d and Mycoplasma hyopneumoniae vaccine in experimental condition

Roman KREJCI Krejci¹, *Philippe Mazerolles¹, Péter Trampus², Nimród Pálmai², Tamás Szalai² (1. Ceva (France), 2. Ceva Phylaxia (Hungary))

Keywords:

Mycoplasma hyopneumoniae,PCV-2d,Vaccine